^
Association details:
| Biomarker: | EGFR exon 19 deletion + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report
Published date:
11/01/2023
Excerpt:
...we present a case of NSCLC with an EGFR exon 19 deletion (19del) and MET gene amplification who developed a severe rash after 2 months of treatment with osimertinib that did not recur after switching to replacement therapy with aumonertinib.
DOI:
10.1080/1120009X.2023.2276574
